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Dengue is the most common vector-borne viral dis-
ease, causing nearly 400 million infections yearly.
Currently there are no approved therapies. Antibody
epitopes that elicit weak humoral responses may
not be accessible by conventional B cell panning
methods. To demonstrate an alternative strategy to
generating a therapeutic antibody, we employed a
non-immunodominant, but functionally relevant,
epitope in domain III of the E protein, and engineered
by structure-guidedmethods an antibody directed to
it. The resulting antibody, Ab513, exhibits high-affin-
ity binding to, and broadly neutralizes, multiple geno-
types within all four serotypes. To assess therapeutic
relevance of Ab513, activity against important human
clinical features of dengue was investigated. Ab513
mitigates thrombocytopenia in a humanized mouse
model, resolves vascular leakage, reduces viremia
to nearly undetectable levels, and protects mice in
a maternal transfer model of lethal antibody-medi-
ated enhancement. The results demonstrate that
Ab513 may reduce the public health burden from
dengue.
INTRODUCTION
Dengue is the most important mosquito-borne viral disease
affecting humans. Half of the world population lives in areas
at risk for dengue, resulting in an estimated 390 million infec-
tions per year globally (Bhatt et al., 2013). Dengue is a self-
limiting, systemic illness caused by any of four dengue virus se-
rotypes, DENV-1 through DENV-4, which share only 60%–75%
identity in amino acid sequence. Infection results in life-longprotection to the infecting serotype but only transient protec-
tion to heterologous serotypes. Currently, there is no specific
treatment available, and the leading vaccine candidate recently
demonstrated limited efficacy, estimated to be between 30%–
60%, with limited to no significant protection against DENV-2
(Capeding et al., 2014; Sabchareon et al., 2012; Villar et al.,
2015).
Passive immunotherapy with monoclonal antibodies repre-
sents a potentially important approach to the treatment of
dengue. Treatment with monoclonal antibodies has been shown
to rapidly and substantially reduce viral titers in several in-
stances, including influenza (Ramos et al., 2015) and HIV (Cas-
key et al., 2015). Therapeutically viable antibodies to infectious
diseases must have a broad coverage of genetically diverse
strains. Such antibodies are typically identified by large-scale
panning exercises of B cells from infected individuals. These ap-
proaches are inherently biased by the native humoral immune
response, and as such, may be limited in accessing epitopes
that elicit no or little humoral response but may yet be function-
ally important target epitopes. Moreover, antibody therapy to
immunodominant regions has the potential to cause immune
interference, such as by masking important epitopes for eliciting
a memory protective response (Siber et al., 1993; Siegrist et al.,
1998; Zhang et al., 2007).
Utilizing panning of B cells derived from infected patients or
challenged mice, a range of DENV-neutralizing antibodies have
been identified, including those with reactivity to multiple sero-
types (Beltramello et al., 2010; Brien et al., 2010; de Alwis
et al., 2011; Lai et al., 2013; Smith et al., 2013). Studies charac-
terizing the human humoral response to DENV infection have
found that it is dominated by antibodies to prM and domain I
and II (DI/II) of the envelope (E) glycoprotein (Beltramello et al.,
2010; Dejnirattisai et al., 2010; Lai et al., 2008). More recent
studies have indicated that antibodies which bind complex, qua-
ternary E protein epitopes on the virus surface (de Alwis et al.,
2012; Fibriansah et al., 2014; Teoh et al., 2012), notably the hingeCell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc. 493
region connecting EDI and EDII, appear to contribute the major-
ity of the human humoral DENV neutralizing activity and may
mediate long-term protection, albeit in a serotype-specific
manner (de Alwis et al., 2012). In contrast, anti-EDIII antibodies
have been shown to constitute a minor proportion of the overall
human humoral response and also contribute little of the anti-
DENV neutralizing activity (Dejnirattisai et al., 2010; Wahala
et al., 2012; Wahala et al., 2009; Williams et al., 2012). Addition-
ally, there have been recent reports of potent antibodies that
bridge E monomers (EDE-directed antibodies) (Dejnirattisai
et al., 2015).
As EDIII-specific antibodies have been shown to constitute a
minor component of the overall human humoral response but
have high potency, we investigated whether targeting EDIII
might represent an important strategy for immunotherapy. How-
ever, existing EDIII-directed antibodies are not fully cross-reac-
tive; while they typically exhibit high potency due in part to
greater antibody accessibility, none have been shown to
neutralize diverse genotypes among all four serotypes. We
recently described the derivation of antibody 4E5A, which was
engineered from 4E11, a mouse antibody directed to an acces-
sible EDIII epitope, without the assistance of crystal structure
information through a structural-physicochemical statistical
approach (Tharakaraman et al., 2013).
Herein, we describe a structural framework developed to char-
acterize the epitope-paratope interface on domain III, thereby
enabling us to engineer an optimized antibody candidate,
Ab513. Ab513 was extensively characterized in vitro and in vivo
to investigate its potential to alter dengue pathogenesis. Ab513
represents an alternative, complementary approach to identifi-
cation of broad-spectrum antibodies, and illustrates an effective
strategy to target non-immunodominant but functionally relevant
epitopes.
RESULTS
Structure-Guided Redesign of 4E5A
Recently, we reported the engineering of antibody 4E5A from
4E11 with improved binding, especially to DENV-4; however,
affinity to DENV-4 was still modest (100 nM) compared to the
other serotypes. Analysis of genetic variability in epitope re-
gions confirms that the region targeted by 4E5A is far more
conserved compared to the EDI/II hinge epitope region. There-
fore, to develop a broad-spectrum potent antibody for dengue
that targets a non-immunodominant epitope, we redesigned
4E5A for improved affinity to DENV-4, leveraging analysis of
the epitope-paratope interface. Adapting from network (graph)
theory, we developed a framework to compute the inter-residue
atomic interactions between interacting amino acid pairs of an
antigen-antibody interface. As such, we define the inter-residue
interactions between a CDR residue and its neighboring epitope
residues, rendered in a 2D graph format, as the epitope-para-
tope connectivity (EPC) network (Experimental Procedures).
CDR mutations or positions (when mutated) that contribute to
more favorable epitope contacts, as evaluated by EPC network
analysis, were investigated experimentally. To wit, absent in the
identification of 4E5A was interrogation of amino acids within
CDR-H1 which, unlike CDR-H3, is positioned at the Ab-Ag494 Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc.interface periphery, thereby potentially allowing for subtle
changes to the binding interface. Therefore, 4E5A CDR-H1
was inspected as a potential region to engineer, to test the
accuracy of our epitope-paratope description and to develop
an optimized immunotherapy candidate targeting a specific
epitope.
First, we hypothesized that subtle differences in the CDR
backbone and/or residue side-chain conformation between the
4E11 model developed earlier (Tharakaraman et al., 2013) and
the crystal structure, published recently (Cockburn et al.,
2012), could have led us to underestimate the significance of
certain CDR residues in our previous design calculations. While
the placement of the majority of the backbone and side-chain
atoms were highly similar (pairwise Ca RMSD of the six CDR
loops, CDR-H1, -H2, -H3, -L1, -L2, -L3, varies from 0.176 to
0.407 A˚), one notable exception was Thr33 of CDR-H1, which
is observed to be in close contact with Lys310, Lys323, and
Val364 of DENV-4 EDIII (Figure S1). In all the DENV-1 to -4 co-
crystal structures (3UZE, 3UYP, 3UZQ, 3UZV), the CG2 carbon
of Thr is proximal to the CG2 carbon of Val364 filling a void be-
tween VH and EDIII, whereas in the homology model, the CG2
carbon points away from Val364 disrupting this hydrophobic
contact. In view of the different side-chain orientation of Thr33,
we hypothesized that a Val in place of Thr at 33 would form a
stronger hydrophobic contact with the Val at 364 of EDIII. This
is evident from the EPC network analysis (Figure 1A). Further-
more, the fact that position 364 is hydrophobic in all DENV-1
to -4 suggests that a Thr33Val mutation would not be detrimental
toward DENV-1 to 3 binding.
Structural analyses coupled with EPC network analysis identi-
fied sites 27–28 and 31–33 of heavy chain as being positioned to
potentially mediate new or improved contacts. To interrogate
these sites, including Thr33Val, site-saturation combinatorial
libraries were generated (Supplemental Experimental Proce-
dures), combined, transformed into yeast, and assessed for
binding to DENV-4 EDIII by scFv surface display using flow cy-
tometry. Relative to 4E5A, the combined library exhibited a pop-
ulation with greater binding, supporting predictions that these
regions are hotspots for improving DENV-4 affinity. After three
rounds of sorting in which the top binders to DENV-4 EDIII
were selected, the FACS profile of the population showed signif-
icant enrichment of cells with enhanced DENV-4 EDIII binding.
Sequencing of 50 clones from this enriched population revealed
four unique variants (Table S1). Interestingly, for the enriched
triple-site variants, all contained a Thr33Val substitution and no
variation was observed at position 32, despite sequencing of
the unsorted library demonstrating that variation at this position
was intact.
We tested the mutations identified by the EPC network anal-
ysis in the context of full-length IgG and found the variants ex-
hibited10- to 20-fold enhanced affinity to DENV-4 EDIII relative
to 4E5A (Table 1, rows 1–4). In this process, we noted that the
Lys31Ser variant introduces a putative N-glycosylation site at
position 29, therefore, this variant was not further pursued. The
single mutation Thr33Val demonstrated the best binding profile
overall (Table 1, row 2), consistent with our EPC network anal-
ysis. Notably, all variants demonstrated enhanced or equivalent
binding to DENV-1 to -3.
Figure 1. Epitope Paratope Connectivity
Network of Putative Affinity-Enhancing Mu-
tations and Structural Impact of Asn360Tyr
Mutation (EDIII) on Antigen-Antibody Inter-
action
(A) The EPC networks observed in 4E11 and
mutant antibodies are shown for examples of pu-
tative affinity enhancing positions. Each of these
EPCs networks is shown as a 2D graph: nodes
represent amino acids (antibody: red; antigen:
blue) and edges represent inter-residue non-co-
valent interactions (black: hydrophobic bonds;
red: hydrogen bonds; yellow: cation pi; green:
ionic). For each position of interest, the EPC
network is given before and after mutation (with
the arrow pointing from the WT to the modeled
structure).
(B) Sequence alignment of EDIII domain of repre-
sentative DENV-4 strains from genotypes I, IIA,
and IIB. 4E5A epitope residues are highlighted in
red. The column corresponding to the Asn360Tyr
mutation, observed in the genotype I strain H241
(Philippines/1956), is highlighted by bold letters.
(C) Close-up view of CDR-H1 and the DE-loop
(residues 358–365) as observed in the 4E11-EDIII
(DENV-4) co-crystal structure (PDB: 3UYP): VH:
green; VL: not shown; EDIII: cyan. Asn360 forms a
water-mediated hydrogen bond (dotted arrows)
with Gly27 of the CDR-H1 loop of 4E11.
(D) Alternate conformers of Tyr360 generated by
modeling are rendered in stick format. The side
chains of these conformers are colored according
to potential steric clashes: yellow-favorable; red-
unfavorable.
(E) Energetic calculations as carried out using
Discovery Studio.Next, we analyzed the conservation of the epitope residues
across serotypes to identify potential DENV-4 ‘‘signature’’ resi-
dues, as these might contribute to the relatively weaker affinity
of 4E5A to DENV-4. Critically, four out of the seven epitope resi-
dues unique to DENV-4 were localized to a region in the loop be-
tween the ‘‘D’’ and ‘‘E’’ b strands (residues 358–365), suggestingCell 162, 493–that differences in this region could be
partly responsible for the lower affinity
binding of 4E5A against DENV-4 strains.
Closer examination of this region indi-
cated that shortening the length of the
proximal antibody CDR-H1 loop via resi-
due deletion would result in the removal
of a ‘‘elbow’’ region (25ASGF28) in the
CDR loop, resulting in roughly an 8% in-
crease in shape complementarity (Law-
rence and Colman, 1993) between the
interacting surfaces (estimated shape
complementarity ‘‘Sc’’ of 4E11 and CDR
deletionmutant are0.65and0.71, respec-
tively). In addition to aiding DENV-4 EDIII
binding, our analysis also suggested that
deletion of a residue in the region 25–28of CDR-H1, notably Ala25, Ser26, or Gly27 of CDR-H1, would
permit the antibody to more efficiently engage DENV-1 to -3 by
virtue of electrostatic interactions between the positively charged
surfaceon theantibodyVHcreatedbyArg99ofCDR-H3andLys3
of FR1 and the negatively charged residues 360–363 of EDIII
(D360, E362 on DENV-1; E360 and D362 on DENV-2; E362 and504, July 30, 2015 ª2015 Elsevier Inc. 495
Table 1. Binding of 4E5A and Variants to EDIII of DENV-1 to 4 Determined by Competition ELISA
Variant (chain)
EDIII-DENV-1 EDIII-DENV-2 EDIII-DENV-3 EDIII-DENV-4
KD (nM) Relative Affinity KD (nM) Relative Affinity KD (nM) Relative Affinity KD (nM) Relative Affinity
4E5A 0.27 0.10 15.8 94.08
T33V (HC) <0.1 >2.7 <0.1 >1.0 0.7 22.6 3.45 27.3
K31Q, T33V <0.1 >2.7 <0.1 >1.0 1.1 14.4 4.13 22.8
G27Y, F28W <0.1 >2.7 <0.1 >1.0 14.5 1.1 5.35 17.6
A25D (HC) 1.27 0.21 <0.3 >0.33 19.9 0.79 297.00 0.32
S26D (HC) <0.3 >0.90 <0.3 >0.33 5.5 2.87 13.80 6.82
G27D (HC) <0.3 >0.90 <0.3 >0.33 9.6 1.65 25.76 3.65
G27P (HC) 4.58 0.06 <0.3 >0.33 37.4 0.42 1936.00 0.05
G27A (HC) <0.3 >0.90 <0.3 >0.33 22.3 0.71 44.70 2.10
Y106R (HC) <0.3 >0.90 <0.3 >0.33 31.3 0.50 318.50 0.30
E97R (LC) 0.36 0.75 <0.3 >0.33 31.6 0.50 120.55 0.78
E97K (LC) 0.37 0.73 <0.3 >0.33 29.1 0.54 112.20 0.84
E97Q (LC) 0.45 0.60 <0.3 >0.33 26.1 0.61 123.25 0.76
Humanized 4E5A <0.1 >2.70 <0.1 >1.0 5.8 2.72 55.08 1.71
Ab513 <0.1 >2.7 <0.1 >1.0 1.2 13.2 4.32 21.8E363 on DENV-3) (Figure 1A and Figure S1B). Additionally, a
fourth mutation—Gly27Pro—was also predicted to have a similar
effect as the deletion since introduction of a Pro residue might
introduce a bend in the loop backbone.
Experimental testing of these variants indicated that two of the
deletion mutants, Ser26D and Gly27D, demonstrated 7-fold
and 3.6-fold greater binding to EDIII of DENV-4 (strain BC287/
97, having Asn at position 360), without being detrimental to
DENV-1 and DENV-2 EDIII affinity (Table 1, rows 5–9). In agree-
ment with the structural predictions, the two deletion mutants
also improved affinity to DENV-3 albeit to a lesser extent. The
Ser26D mutant improved affinity to DENV-4 strain H241 EDIII
(containing Tyr at 360) to 240.9 nM, a 19-fold improvement
when compared to the parent 4E5A antibody. Notably, other
putative affinity-enhancing amino acid substitutions that were
predicted from a standard structure-based rational design,
including Glu97Arg/Lys and Tyr106Arg, were found to have mar-
ginal or no improvement based on EPC network analysis (Fig-
ure 1)—a result that was verified experimentally (Table 1, rows
10–13). The final engineered antibody, Ab513, differs from
4E11, the starting antibody, through introduction of six affinity-
enhancing point mutations and an affinity-enhancing deletion
at position 26 (VH) and amino acid changes to humanize the
candidate. Relative to 4E5A, Ab513 exhibits a 13- and 22-fold
affinity improvement to DENV-3 and DENV-4, respectively, while
showing smaller gains to DENV-1 and DENV-2 (Table 1).
The Structure of the Ab513-EDIII Complex
To verify the structure-based predictions of affinity-enhancing
mutations and to cross-compare 4E11 against Ab513, we solved
the crystal structure of Ab513 (reformatted as a scFv) bound to
EDIII of DENV-4. Two crystal forms were obtained providing a
total of eight independent views of the complex (Table S2). The
crystal asymmetric unit of form I contains six scFv-EDIII com-
plexes arranged as three dimers (Figure 2A). The scFvs in each
dimer are related by a non-crystallographic dyad (Figure 2C)496 Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc.adopting a ‘‘swapped’’ configuration. Crystal form II (Figure 2B),
however, comprises two independent monomeric mAb513scFv-
DIII complexes (related by a non-crystallographic dyad).
Notably, the temperature factors for the antigen in both crystal
forms (temperature factors of DIII in form I and II are 80.5 and
120.4 A˚2 respectively) exceed that of the scFv moiety (form I,
II: 47.5, 70.4 A˚2), indicating greater flexibility. Nevertheless, the
eight complexes do not differ significantly from each other
(average pairwise rmsd of 0.457 A˚).
As expected, Ab513 recognizes the A-strand epitope on EDIII,
with the heavy and light chain domains contacting the A and G b
strands, respectively. The overall scFv-EDIII complex structure
is similar to the 4E11-EDIII complex (PDB: 3UYP) with a root-
mean-square deviation (rmsd) of 0.463 A˚, indicating that the
epitopes recognized by these two antibodies are nearly superim-
posable. Examination of the epitope-paratope interface reveals
that the side chains of the six affinity-enhancing substitutions
(Thr33Val and Ala55Glu of VH; Arg31Lys, Asn57Glu, Glu59Gln
and Ser60Trp of VL) make the predicted contacts, with no signif-
icant deviations observed at any of the contact positions (Fig-
ure S2). Further, it is observed that the deletion of Ser26 results
in higher surface complementarity with the antigen due to
removal of the ‘‘elbow’’ present in 4E11, as predicted (Figure 2D).
It should be noted that the deletion does not alter the canonical
conformation (Chothia et al., 1989) of the H-CDR1 loop (Chothia
type 1). A total of 898 A˚2 of accessible surface area of Ab513 is
buried in the Ab513-EDIII interface with the VH and VL making
contact surface areas of 480 and 418 A˚2, respectively. Twenty
H-bonds and 13 salt bridge interactions are found across the
Ab513-EDIII interface, whereas 16 H-bonds and 8 salt bridges
are found across the 4E11-EDIII interface, indicating improved
contacts as the principal reason of affinity enhancement.
Ab513 Neutralizes a Wide Range of DENVs
To assess the breadth of binding of Ab513, the antibody was
tested against a panel of 21 EDIII proteins, which represent a
Figure 2. scFv Ab513-EDIII (DENV-4, BC287/
97 (Mexico/1997)) Complex Structure
(A–D) The asymmetric unit of crystal forms I (A) and
II (B) contain six and two Ab513-EDIII complexes,
respectively. The scFvs of form I are rendered in
solvent accessible surface format and the EDIII
domains are rendered in cartoon format. The
interface formed by the heavy chains of the two
ScFvs in the dimer is shown in C. (D) Comparison
of the antibody-EDIII interface for Ab513 (left) and
4E11 (right) demonstrating that deletion of Ser26
results in higher surface complementarity due to
removal of the ‘‘elbow’’ present in 4E11.set of diverse challenge strains selected, in part, for having diver-
sity within the epitope region. Ab513 was able to bind all EDIII
proteins and demonstrated affinity improvement relative to
4E5A by asmuch as 40-fold against DENV-3 and DENV-4 strains
while marginally increasing the affinity against DENV-1 and
DENV-2 strains (Table 2). Consistent with its strong binding,
Ab513 demonstrated strong in vitro neutralization of DENV-1
to -4, with observed EC50 values of <200 ng/ml for all four sero-
types (Table 2), a substantial enhancement compared to 4E11
(Figure S3).
The compact yet dynamic surface structure of flaviviruses,
including DENV, impacts epitope accessibility and thereby anti-
body neutralization activity (Lok et al., 2008; Sukupolvi-Petty
et al., 2013). Therefore, extending beyond the binding studies,
we performed a series of neutralization studies to characterize
further the activity of Ab513. First, to validate the affinity gain
observed by Ser26Dmutation to DENV-4 strain H241 (containing
a bulky Tyr at position 360) EDIII protein, as predicted by struc-
tural modeling analyses, we also tested Ab513 for in vitro
neutralization against this strain. Compared to 4E5A, Ab513 ex-
hibits a 4-fold improvement in neutralization potency to H241,Cell 162, 493–with an EC50 of about 2 mg/ml. Next, to
challenge Ab513 neutralization breadth,
we performed a bioinformatic analysis of
strains available from the World Refer-
ence Center for Emerging Viruses and
Arboviruses to identify diverse isolates
having sequence diversity within and
near the Ab513 epitope region. This anal-
ysis resulted in the identification of 12 iso-
lates, three from each serotype, which
collectively represent a true challenge
panel of viruses that are most likely to
be refractory to Ab513 neutralization.
Ab513 was able to fully neutralize
all tested challenge viruses, with 9 of
12 viruses yielding EC50 values of
<0.5 mg/ml, and the remaining three vi-
ruses neutralized at <4 mg/ml (Table S3).
To further assess and compare Ab513
with other DENV-neutralizing antibodies,
we performed comparison studies of
in vitro neutralization. We note that varia-tions exist in methods of measuring in vitro neutralization of
DENV, and studies have shown that even when using the same
method, substantial titer/EC50 differences are often observed
between laboratories with the same antibody samples (Rain-
water-Lovett et al., 2012; Thomas et al., 2009). We therefore per-
formed side-by-side direct comparisons, first against four of the
most potent antibodies from the recently described EDE class of
antibodies (Dejnirattisai et al., 2015). Results demonstrated that
Ab513 exhibits similar or better potency than EDE mAbs of sub-
class 1 and comparable activity to those of subclass 2, which are
sensitive to glycosylation state of DENV (Table S4). We also
directly compared Ab513 with a representative fusion loop-
directed antibody (4G2) (Henchal et al., 1982), two DI/II hinge
epitope-directed antibodies (14c10 and 1F4) (de Alwis et al.,
2012; Teoh et al., 2012), and a potent human cross-reactive anti-
body directed to DIII (DV87.1) (Beltramello et al., 2010). Ab513
showed greater potency than the fusion-loop mAb, comparable
activity to the potent DIII-directed mAb and one DI/II hinge-
directed mAb and slightly lower potency than the other DI/II
hinge-directed mAb (Figure S4). Collectively, these results
demonstrate that Ab513 is able to efficiently neutralize a broad504, July 30, 2015 ª2015 Elsevier Inc. 497
Table 2. Ab513 Breadth of Binding to Diverse Genotypes Determined by Competition ELISA and SPR, with In Vitro Neutralization of
Select Strains
Serotype EDIII strain ELISA KD (nM)
Fold increase
from 4E5A SPR KD (nM) EC50 (ng/ml)
a
I Hawaii/1944 <0.1 NDb 0.041 67 ± 12
Vietnam/2008 <0.1 ND 0.039
Malaysia/2005 <0.1 ND 0.064
Mexico/2007 <0.1 ND 0.071
II New Guinea/1944 (NGC) <0.1 ND 0.015 190 ± 55
Singapore/2008 <0.1 ND 0.024
Peru/1995 <0.1 ND 0.012
Vietnam/2007 <0.1 ND 0.014
Venezuela/2007 <0.1 ND 0.029
IIII Philippines/1956 (H87) 1.24 12.8 1.0 97 ± 20
Singapore/2009 0.35 18.3 0.6
Nicaragua/2010 3.36 9.5 4.9
Puerto Rico/1977 1.36 9.3 1.4
Cambodia/2008 1.32 10.1 2.5
IV Mexico/1997 (BC287/97) 4.32 21.8 3.8 79 ± 30
Singapore/2010 8.43 14.4 6.1
New Caledonia/2009 10.81 15.9 8.9
Philippines/1956 (H241) 113.10 40.7 118.5 2,300 ± 1,500
Brazil/2011 14.68 18.2 7.9
Venezuela/2008 4.50 11.9 3.0
Thailand/1997 611.60 6.6 >300c
aAverage ± SEM, from three independent experiments.
bND, not determined.
cAffinity estimate based on curve.panel of challenge viruses which contain sequence diversity
within the epitope region and which represent genotypic and
geographical diversity of DENV. Additionally, Ab513 is able to
neutralize virus more strongly than fusion loop-directed anti-
bodies and with similar or better potency than the most potent
EDE antibodies.
Ab513 Neutralizes DENV Despite Fc Receptor-Mediated
Phagocytosis
Secondary infection with a heterologous DENV serotype has
been associated with more severe illness; one mechanism that
has been posited to explain this observation is antibody-medi-
ated enhancement of virus uptake through the Fc receptor
upon virus binding with either a non-neutralizing antibody, for
example to prM, or binding of a neutralizing antibody at sub-
neutralizing concentrations. Therefore, we investigated the abil-
ity of Ab513 to enhance virus uptake in the context of an ex vivo
model.
We compared the extent of enhanced virus replication with
Ab513 and a chimeric version of the fusion loop-directed anti-
body, 4G2, in Fc-receptor bearing cells. Significantly lower levels
of enhancement were observed with Ab513 as compared to 4G2
against all four DENV serotypes (Figure 3A). Since neutralization
of the homologous DENV serotype can occur in the presence of
Fc receptor-mediated phagocytosis, whereas heterologous498 Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc.DENV neutralizes by inhibiting uptake (Chan et al., 2011), we as-
sessed the ability of Ab513 to neutralize the four DENV in the
presence of cellular uptake. We examined the fate of fluores-
cently labeled DENV with the highest dilution of antibodies that
resulted in complete virus neutralization in THP-1 cells. Then,
the localization of DENV-immune complexes was visualized
by immunofluorescence. Ab513 neutralized all four DENV sero-
types in the presence of uptake, with DENV-immune complexes
trafficked to the LAMP-1 compartment (Figure 3B). This is in
contrast to chimeric 4G2 (and 4E5A, data not shown) where
DENV was neutralized by inhibition of initial virus uptake (Fig-
ure 3C). Collectively, these results demonstrate that Ab513 can
neutralize all DENV serotypes in the presence of phagocytosis,
which has been previously observed exclusively when convales-
cent serum samples were reacted with the homologous but
not heterologous DENV serotypes (Chan et al., 2011; Wu et al.,
2012).
Ab513 Demonstrates Activity in Multiple Mouse Models
Capturing Key Clinical Features of Disease
Severe dengue infection is associated with increases in vascular
permeability, which can lead to life-threatening hypovolemic
shock. The increased permeability is often accompanied by
thrombocytopenia. Currently, there are no specific therapies
for treating dengue and management consists of supportive
Figure 3. Effects of Antibody on DENV Uptake in a Monocytic
Cell Line
(A) Enhanced virus infection in THP-1.2S cells with addition of either chimeric
4G2 or Ab513.
(B) Analysis of Ab513 and DENV localization in THP-1.2S cells. The late
endosomal and lysosomal compartments of cells were stained by LAMP-1.
(C) Analysis identical to (B) except chimeric 4G2 is used as antibody.care only. Therefore, development of a therapeutic strategy that
attenuates the duration and severity of symptoms and/or
reduces the incidence of these major complications is of clinical
importance (Simmons et al., 2012). To test the hypothesis of
whether an immunotherapy can reduce clinical signs and symp-
toms of DENV infection, we deployed Ab513 in a set of animal
models havingmultiple relevant endpoints: (1) viremia, (2) throm-
bocytopenia, (3) vascular leak/permeability, and (4) antibody-
enhanced disease.
To test the ability of Ab513 to reduce viremia, we administered
Ab513 to 7- to 10-week-old AG129 mice infected with DENV-2.
While the AG129mousemodel has potential limitations, wewere
particularly interested in whether we could prevent virus from
migrating to the CNS. In this model, using DENV-2 strain NGC
as the infective agent, administration of 25mg/kg of an irrelevant
isotype-matched antibody (‘‘Ctl. mAb’’) 24 hr prior to virus injec-
tion had no effect on CNS-related migration of virus, paralysis,
and death. In contrast, a single prophylactic administration of
Ab513 at 5 mg/kg resulted in survival of 6/10 animals (p <
0.0001) out to day 31 post-challenge, indicating elimination of
most virus, little to no migration of DENV-2 to the CNS, and pro-
tection against CNS-related symptoms, such as paralysis (Fig-
ures 4A and 4B). This effect was even more pronounced at
25 mg/kg, where 9/10 animals survived. This increase in survival
was also reflected in measurement of viremia levels at day 3
post-infection, the day of peak viremia in this model (Figure 4A).
Administration of 5 mg/kg of Ab513 resulted in a 1.7 log10 reduc-
tion in viral titer; a 2.4 log10mean reduction was observed inmice
treated with 25 mg/kg Ab513, with three of the animals in this
group having titers below the limit of detection. We note that
the typical read-outs of this model are viremia at day 3 or
following animals for 14–21 days, prior to evidence of CNS-
related symptoms. However, as demonstrated here, a single
dose of Ab513 is able to effectively neutralize the virus and pre-
vent migration of virus to the CNS.
Next, we directly tested the prophylactic and therapeutic po-
tential of Ab513 in the context of platelet loss upon DENV infec-
tion. To this end, we adapted a recently reported humanized
mice (humice) dengue model developed using DENV-2. Humice
were reconstituted with human blood lineage cells, leading to
production of a significant level of human platelets. We have
shown previously that DENV infection in humice reproduces
some key features of dengue in human, most notably thrombo-
cytopenia (Sridharan et al., 2013). Critically, the reduction in
platelet count occurs with human but not mouse platelets, thus
allowing us to evaluate if Ab513 can specifically prevent human
thrombocytopenia, in vivo. We applied the same infection
approach with clinical isolates representing all four DENV sero-
types for evaluation of Ab513, without any adaptation. Humice
challenged with virus only or virus with isotype control antibody
display a sharp reduction of human platelets after virus infection,Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc. 499
Figure 4. In Vivo Activity of Ab513 in AG129 and Humanized Mice
(A) AG129 mice (n = 10) were treated with Ab513, an irrelevant IgG1mAb (‘‘Isotype control’’), or PBS prior to challenge with 106.4 CCID50 of DENV-2. Viremia from
serum 3 days post-infection (dpi) was measured by qRT-PCR. Dotted line represents limit of detection. The three dots on the x axis represent values (samples)
below the lower limit of detection.
(B) A separate cohort of animals were monitored for survival. ***p < 0.0001, as compared with PBS controls.
(C–F) Comparison of human platelet levels in uninfected and infected humanized mice (humice) without treatment or treated with an isotype control Ab (‘‘Control
Ab’’) or Ab513. The dashed line indicates the average of human platelet counts in uninfected humice. Results are shown as the average counts of human platelets
per microliter of blood at different days post-infection (n = 5–7). **p < 0.05. Log-rank (Mantel-Cox) statistical test was performed to assess for significance. Error
bars denote SD.with the nadir typically observed 2–3 days post challenge fol-
lowed by a gradual recovery (Figures 4C–4F). Humice receiving
a single administration of Ab513 (25 mg/kg) either 24 hr prior to
or after virus challenge demonstrated a significantly accelerated
recovery of human platelet levels (Figures 4C–4F), with a more
dramatic impact on humice challenged with DENV-1 and
DENV-2 (Figures 4C and 4D). In contrast, mouse platelet levels
were not affected by virus infection or by Ab513 administration
(Figure S5). Quantification of virus levels in sera (as determined
by plaque assay) from humice challenged with DENV-1 and
DENV-2 showed a significant reduction in viral load by adminis-500 Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc.tration of Ab513 prior to or post-infection. DENV-4 viremia could
not be detected by plaque assay or qRT-PCR and DENV-3
viremia could only be detected by qRT-PCR but mostly near
the limit of detection, precluding a robust analysis (Figure S5).
Despite the current limitations of this model in the context of
the DENV-3 and DENV-4 clinical isolates, our data indicate that
treatment with Ab513 shortened the duration of human thrombo-
cytopenia. Additionally, levels of IFN-g and IL-10 were markedly
reduced in DENV-2 challenged humice treated with Ab513 in
comparison to those that received no Ab or the control sero-
type-specific mAb. A significant reduction in IFN-g was also
Figure 5. Ab513 Protects Animals from Enhanced Disease
(A) Five- to six-week-old AG129 mice born to DENV-1 immune mothers were
infected with DENV-2; included was an uninfected control (black). On day 1
post-infection, infected mice were either treated with 25 mg/kg of Ab513
(green) or isotype control antibody (red). On day 6 post-infection, the extent of
vascular leakage in the mice were assessed by Evans blue assay. **p < 0.01
based on the Mann-Whitney test with reference to the isotype control.
(B and C) A group of A129 infected pupswas followed daily. (B) Survival curves
of four cohorts (n = 8): untreated, receiving a control antibody (Ctrl mAb), or
5 mg/kg or 25 mg/kg Ab513. Statistical inferences were made by pairwise
comparisons for each treatment group to the control group, considering the
survival of both. Ab513 at all doses had a significant effect on survival, log-rank
(Mantel-Cox) test, p < 0.0001). (C). Assessment of mean clinical score of the
three treatment cohorts.observed in DENV-4 challenged humice in response to adminis-
tration of Ab513. These results demonstrate that a single dose of
Ab513 administered before or after infection is able to effectively
prevent thrombocytopenia or accelerate recovery of human
platelets to normal levels in humanized mice across all four
DENV serotypes. Additionally, in the more robust models of
DENV-1 and -2, Ab513 causes a significant reduction in viremia
in humanized mice, consistent with the data generated in the
AG129 mouse.
In addition to thrombocytopenia, another crucial aspect to
address in use of an immunotherapy for dengue treatment is
whether it can mitigate vascular leakage. Therefore, we as-
sessed the extent of vascular leakage in Ab513-treated
DENV2-infected mice by Evans Blue assay on day 6 post-infec-
tion, the time point at which the isotype control mice were mori-
bund and expected to display significant increased vascular
permeability (Ng et al., 2014). Evans’ blue dye binds strongly to
albumin present in the blood and the amount of the dye detected
in perfused organs is proportional to the extent of vascular
leakage. In the AG129 ADE model, significant vascular leakage
can be detected in the liver, intestine, spleen, and kidney of in-
fected mice born to immune mothers (Ng et al., 2014). In this
model, a significant increase in vascular leakage was observed
in the isotype antibody-treated mice compared to control mice
asmeasured by elevated Evans Blue content in their livers, intes-
tines, spleen, and kidneys (Figure 5A). Upon treatment with
Ab513 on day 1 post-infection, the extent of vascular leakage
detected for all the organs was significantly reduced (Figure 5A).
Taken together, this data indicates that Ab513 treatment signif-
icantly limited the extent of vascular leak in key organs.
Finally, for Ab513 to be useful therapeutically to treat dengue,
this antibody must be able to compete with heterologous anti-
bodies that could enhance DENV infection of Fc-receptor
bearing cells. This is particularly relevant since severe dengue
is more common in patients having secondary infection with a
DENV serotype heterologous to initial infection. To test whether
our antibody can be effective under such circumstances, we
examined whether Ab513 could mitigate enhanced disease
caused by heterotypic antibodies. Consistent with previous re-
ports (Ng et al., 2014), a sublethal challenge with 106 PFU of
DENV-2 of A129 pups from DENV naive mothers resulted in a
transient infection with 100% survival. In contrast, 100% of
pups from DENV-1 immune mothers reached moribund state
on day 4 post-DENV-2 infection (Figure 5B), indicating that these
animals underwent enhanced disease severity mediated by
maternally acquired heterologous DENV antibodies. The protec-
tion efficacy of Ab513 in the presence of these heterologous
enhancing antibodies was then determined by treating the in-
fected pups from DENV-1 immune mother with 25 mg/kg or
5 mg/kg of Ab513 on day 1 post-infection. Ab513 treatment
was able to efficiently prevent disease enhancement in these in-
fected pups with 100% and 88% survival rate, respectively (Fig-
ure 5B). In sharp contrast, administration of an isotype Ab control
resulted in 100% mortality on day 4 post-infection. Notably, the
mice from the treatment groups displayedmild diarrhea but were
still very active on day 4 post-infection. In contrast, infected an-
imals administered an isotype control displayed ruffled fur, se-
vere diarrhea, hunched backs and lethargy (Figure 5C). A doseCell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc. 501
response was observed for Ab513, with more rapid recovery
time associated with the higher antibody dose.
DISCUSSION
In this study, we sought to address the question of whether
an engineered anti-DENV antibody targeted to a non-immundo-
minant—but functionally relevant—epitope could be used for
immunotherapy. Importantly, development of such a strategy
to treat dengue, unlike most other infectious agents such as
influenza virus or HIV, faces a unique set of challenges arising
from the fact that DENV antibodies potentially have the capacity
tomediate protection or exacerbate disease. Additionally, recent
discovery of antibodies that neutralize DENV-1 to -4 and bind
epitopes that span two adjacent E monomers within a single
dimer (EDE-directed antibodies) raises interesting and important
questions with regards to the human immunological response
(Dejnirattisai et al., 2015). While EDE antibodies exhibit potent
pan-serotype neutralizing activity, they have features which
may limit their potential as effective immunotherapies. First,
they have long CDR-H3 loops (15–27 amino acids) with a high
level of Tyr residues. Both these features have been linked
to antibody polyreactivity (Mouquet and Nussenzweig, 2012;
Wardemann et al., 2003). Additionally, activity of many EDE
antibodies is dependent on glycosylation state of the virus,
thereby limiting their breadth and providing potential viable
escape mechanisms (Dejnirattisai et al., 2015).
Our structure-based EPC network analysis enabled the suc-
cessful prediction of a CDR-proximal deletion to enhance
epitope-paratope complementarity. Engineering of Ab513 vali-
dates the EPC network approach, enabling a structural under-
standing of antibody diversification with regards to antigen
engagement, thereby providing a complementary tool to existing
genetic approaches that aim to trace the development of broadly
neutralizing antibodies from germline (Lingwood et al., 2012;
Pappas et al., 2014).
Ab513 exhibits broad binding and neutralization, regardless of
virus genotype, neutralizes all four DENV serotypes even in the
presence of FcR-mediated uptake, and demonstrates in vivo
efficacy against all four DENV serotypes. Taken together, these
data demonstrate that an immunotherapy has the potential to
effectively control viremia and disease in humans.
EXPERIMENTAL PROCEDURES
Materials
Cell culture and virus propagation were carried out as previously described
(Tharakaraman et al., 2013). Briefly, viruses were procured from ATCC or
BEI Resources and propagated in C6/36 or Vero cells using an MOI of approx-
imately 0.1, and harvested after 4–7 days, depending on the strain. Aliquots
were stored at 80C. For breadth of neutralization studies, the 12 viruses
were obtained from the UTMB World Reference Center for Emerging Viruses
and Arboviruses (WRCEVA) repository.
Computation of Epitope-Paratope Connectivity Network of Dengue
EDIII-Antibody Complexes
The X-ray co-crystal structures of 4E11 in complex with the EDIII antigen (PDB:
3UYP [DENV4], 3UZE [DENV3], 3UZV [DENV2], 3UZQ [DENV1]) were used to
determine the various inter-residue inter-atomic contacts across the antigen-
antibody interface, including putative hydrogen bonds (including water-502 Cell 162, 493–504, July 30, 2015 ª2015 Elsevier Inc.bridged ones), disulfide bonds, pi-bonds, polar interactions, salt bridges,
and Van derWaals interactions (non-hydrogen) as described previously (Soun-
dararajan et al., 2011). The interactions between a CDR residue and its neigh-
boring epitope residues are represented by a 2D network graph as a visual aid,
where nodes represent amino acids and the edges represent inter-residue
non-covalent interactions (black: hydrophobic bonds; red: hydrogen bonds;
yellow: cation pi; green: ionic).
Structure Determination, Refinement, and Analysis
Data were collected at a wavelength of 1.00 A˚ at the Swiss Light Source beam-
line PXIII using a Pilatus 6M detector (Dectris, Baden, Switzerland). Indexing,
integration, and merging of the intensities were carried out with program
XDS (Kabsch, 2010) and scaling was performed using programSCALA (Evans,
2006). Data collection statistics are summarized in Table S2. The structure of
form I crystals was determined by molecular replacement using scFvE11 and
DIII DENV4 as individual search probes (Cockburn et al., 2012). The molecular
model was rebuilt using COOT and refined with REFMAC (Winn et al., 2011).
Subsequently, a second crystal form (form II) diffracting to higher resolution
(2.49 A˚) was obtained in the monoclinic space group P21 with two scFv513-
DIII complexes per asymmetric unit. The data were collected by exposing
two different regions of the prismatic crystals and processed using the same
packages. The structure was solved by molecular replacement using the
refined coordinates obtained from crystal form I and the structure was refined
using REFMAC. Figures were prepared in PyMOL (http://pymol.sourceforge.
net) and the structure was validated using the Molprobity web server (http://
molprobity.biochem.duke.edu). Structural superimpositions, buried surface
areas and inter-molecular contacts were calculated using programs LSQKAB,
AREAIMOL, SC, and NCONT from the CCP4 package (Winn et al., 2011).
Assessment and Visualization of DENV Fate in the Presence of
Antibody
THP-1.2S was subcloned from THP-1 by limiting dilution (Chan et al., 2014).
DENV-1 (06K2402DK1), DENV-2 (ST), DENV-3 (05K863DK1), and DENV-4
(06K2270DK1) are clinical isolates. For visualization of DENV immune com-
plexes, DiD-labeled DENV was incubated with media, antibodies, or serum
for 1 hr at 37C before adding to cells at MOI 10. Uptake was assessed as
described previously (Chan et al., 2011).
Administration of Ab513 in a Humanized Mouse Model
All experiments were performed in compliance with the guidelines of the insti-
tutional committees at the National University of Singapore and Massachu-
setts Institute of Technology. Humanized mice were generated as previously
described (Sridharan et al., 2013). Experiments were initiated 1 week before
infection with the i.v. administration of 300 mg/kg human immune globulins
(IVIG, GAMMAGARD [BAXTER]) twice a week to ensure normal levels of circu-
lating IgG. Humice were infected by tail vein injection of 1 3 107 PFU of virus
(DENV2 strain 05K3295) in 200 ml of RPMI 1640 medium. IVIG administration
continued during the infection period. Uninfected humice reconstituted with
the same batch of fetal liver cells were injected with 200 ml of RPMI medium.
Humice were prophylactically (24 hr before DENV infection) or therapeutically
(24 hr after infection) administered with 25 mg/kg of Ab513 or an isotype con-
trol antibody (control Ab) intravenously (i.v). Plaque assay and platelet counts
were performed as described (Sridharan et al., 2013). Results are shown as
means ± SEM except for viremia which presented as a median. Differences
were compared by using ANOVA followed by Student-Newman-Keuls
post hoc analysis. Results with a p < 0.05 were considered significant. All cal-
culations to examine differences between cohorts were completed using
GraphPad Prism v5.0 (GraphPad Software).
Maternal Transfer Model and Measurement of Vascular Leakage
Five- to six-week-old AG129 pups that were born to DENV1-immune mothers
were infected via the subcutaneous route with 103 PFU of DENV2 (D2Y98P-
PP1) diluted in 0.1 ml of sterile PBS. On day 1 post-infection, mice received
the respective treatments, either control antibody or Ab513, via the intrave-
nous (i.v.) route. The mice were then monitored twice daily for their survival
and clinical score for a period of 27 days (0: healthy; 1: ruffled fur; 2: hunched
back; 3: severe diarrhea; 4: lethargic; 5: moribund). In addition, on day 6
post-infection (the time point at which mice from the isotype antibody-treated
group became moribund), Evans blue assay was performed on 5 mice per
group (infected control, isotype control, 5 mg/kg and 25 mg/kg group) as pre-
viously described (Ng et al., 2014). An uninfected control group, comprising
age-matched AG129 mice, was included to obtain the baseline absorbance
readings.
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